Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

NHS patients missing out on new cancer treatments available in other countries, report finds
NHS patients missing out on new cancer treatments available in other countries, report finds
NHS patients are missing out on new cancer treatments because health chiefs are failing to negotiate better prices for drugs, two leading cancer charities have warned.
Turkey’s pharmaceutical industry set to hit $5.53 Billion by 2020, says GlobalData
Turkey’s pharmaceutical industry set to hit $5.53 Billion by 2020, says GlobalData
The pharmaceutical market in Turkey is set to rise from $5 billion in 2015 to $5.
Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin® Combination in Relapsed Renal Cell Carcinoma
Cerulean Announces Results from Phase 2 Clinical Trial of CRLX101 and Avastin® Combination in Relapsed Renal Cell Carcinoma
WALTHAM, MA, USA I August 17, 2016 I Cerulean Pharma Inc.
J&J Remicade Patent Found Invalid in U.S. Victory for Pfizer
J&J Remicade Patent Found Invalid in U.S. Victory for Pfizer
A federal judge in Boston invalidated a key patent on Johnson & Johnson’s blockbuster arthritis drug Remicade, increasing the odds that Pfizer Inc.
Scientists make malaria 'breakthrough'
Scientists make malaria 'breakthrough'
Australian scientists believe they've found a new and more effective way to cure people of malaria by stimulating the immune system to fight the disease.
BD Receives FDA Clearance for New Syringe Designed for the Administration of Humulin R U-500 Insulin
BD Receives FDA Clearance for New Syringe Designed for the Administration of Humulin R U-500 Insulin
FRANKLIN LAKES, N.
Hartmut Retzlaff resigns from office
Hartmut Retzlaff resigns from office
Bad Vilbel, August 15, 2016 – Today STADA Arzneimittel AG and its long-serving chairman of the management board Hartmut Retzlaff agreed on terminating their service relationship due to personal circ...
FDA grants breakthrough therapy designation for depression drug
FDA grants breakthrough therapy designation for depression drug
Following successful phase II trials, the US Food and Drug Administration (FDA) have granted a Breakthrough Therapy Designation for Janssen‘s esketamine, an antidepressant medication, for th...
CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
CASI Pharmaceuticals Provides Update On Phase 2 Trial Of ENMD-2076 In Fibrolamellar Carcinoma
ROCKVILLE, MD, USA I August 16, 2016 I CASI Pharmaceuticals, Inc.
Merck cuts 148 jobs after giving up on ex-blockbuster hopeful Zontivity
Merck cuts 148 jobs after giving up on ex-blockbuster hopeful Zontivity
Merck & Co.
EMA nails Artemis India plant over simvastatin API manufacturing issues
EMA nails Artemis India plant over simvastatin API manufacturing issues
Another Indian API maker is in trouble over manufacturing issues.
Why is breast cancer common but heart cancer rare?
Why is breast cancer common but heart cancer rare?
Malignant cancers strike certain organs, such as the colon or breast, more often than others.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand